Propafenone in restoring sinus rhythm among patients with persistent atrial fibrillation. PROMETEY – an open, multicenter, pilot study performed in the Russian Federation (part II)
Aim. To study efficacy and safety of propafenone (450 mg/d per os) in maintaining sinus rhythm among patients with persistent atrial fibrillation (AF). Material and methods. The study included 200 patients with persistent AF, aged 39-68 (mean age 56.4±4.2 years), from 10 Russian regions. For AF paro...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2005-10-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1006 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839578206033674240 |
|---|---|
| author | I. G. Fomina A. I. Tarzimanova A. V. Vetluzhsky A. A. Abramova |
| author_facet | I. G. Fomina A. I. Tarzimanova A. V. Vetluzhsky A. A. Abramova |
| author_sort | I. G. Fomina |
| collection | DOAJ |
| description | Aim. To study efficacy and safety of propafenone (450 mg/d per os) in maintaining sinus rhythm among patients with persistent atrial fibrillation (AF). Material and methods. The study included 200 patients with persistent AF, aged 39-68 (mean age 56.4±4.2 years), from 10 Russian regions. For AF paroxysm prevention, all patients received propafenone (Propanorm, 450 mg per os, 3 times per day) for 9 months. Results. Propafenone (450 mg/d) restored sinus rhythm in 148 patients (74%) after one month of treatment, in 122 (61%) after 3 months, and in 90 (45%) after 9 months. Propafenone was effective and well tolerated: during 9-month therapy, only 8 patients (4%) complained of dyspepsia, which regressed without additional therapy or treatment discontinuation. Arrhythmogenic effects of propafenone were not registered. In 7 patients (3.5%), PQ interval increased significantly, by 18% comparing to baseline, but the parameter stayed in the normal range. Moderate increase of QT interval (+28%), without being over 460 ms, was observed in 8 patients (4%), and did not require therapy discontinuation. Conclusion. According to the results of open, multi-center study “PROMETEY”, propafenone (450 mg/d per os) was effective and safe for maintaining sinus rhythm in patients with persistent AF. In patients with normal left ventricular ejection fraction, propafenone did not affect inotropic myocardial function. |
| format | Article |
| id | doaj-art-1d58d8e1c45e42839cc8ff1d5373f7c0 |
| institution | Matheson Library |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2005-10-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-1d58d8e1c45e42839cc8ff1d5373f7c02025-08-04T12:50:09Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252005-10-01456265720Propafenone in restoring sinus rhythm among patients with persistent atrial fibrillation. PROMETEY – an open, multicenter, pilot study performed in the Russian Federation (part II)I. G. Fomina0A. I. Tarzimanova1A. V. Vetluzhsky2A. A. Abramova3I.M. Sechenov Moscow Medical Academy, MoscowI.M. Sechenov Moscow Medical Academy, MoscowI.M. Sechenov Moscow Medical Academy, MoscowI.M. Sechenov Moscow Medical Academy, MoscowAim. To study efficacy and safety of propafenone (450 mg/d per os) in maintaining sinus rhythm among patients with persistent atrial fibrillation (AF). Material and methods. The study included 200 patients with persistent AF, aged 39-68 (mean age 56.4±4.2 years), from 10 Russian regions. For AF paroxysm prevention, all patients received propafenone (Propanorm, 450 mg per os, 3 times per day) for 9 months. Results. Propafenone (450 mg/d) restored sinus rhythm in 148 patients (74%) after one month of treatment, in 122 (61%) after 3 months, and in 90 (45%) after 9 months. Propafenone was effective and well tolerated: during 9-month therapy, only 8 patients (4%) complained of dyspepsia, which regressed without additional therapy or treatment discontinuation. Arrhythmogenic effects of propafenone were not registered. In 7 patients (3.5%), PQ interval increased significantly, by 18% comparing to baseline, but the parameter stayed in the normal range. Moderate increase of QT interval (+28%), without being over 460 ms, was observed in 8 patients (4%), and did not require therapy discontinuation. Conclusion. According to the results of open, multi-center study “PROMETEY”, propafenone (450 mg/d per os) was effective and safe for maintaining sinus rhythm in patients with persistent AF. In patients with normal left ventricular ejection fraction, propafenone did not affect inotropic myocardial function.https://cardiovascular.elpub.ru/jour/article/view/1006atrial fibrillationpropafenonesinus rhythm maintenancemulticenter study |
| spellingShingle | I. G. Fomina A. I. Tarzimanova A. V. Vetluzhsky A. A. Abramova Propafenone in restoring sinus rhythm among patients with persistent atrial fibrillation. PROMETEY – an open, multicenter, pilot study performed in the Russian Federation (part II) Кардиоваскулярная терапия и профилактика atrial fibrillation propafenone sinus rhythm maintenance multicenter study |
| title | Propafenone in restoring sinus rhythm among patients with persistent atrial fibrillation. PROMETEY – an open, multicenter, pilot study performed in the Russian Federation (part II) |
| title_full | Propafenone in restoring sinus rhythm among patients with persistent atrial fibrillation. PROMETEY – an open, multicenter, pilot study performed in the Russian Federation (part II) |
| title_fullStr | Propafenone in restoring sinus rhythm among patients with persistent atrial fibrillation. PROMETEY – an open, multicenter, pilot study performed in the Russian Federation (part II) |
| title_full_unstemmed | Propafenone in restoring sinus rhythm among patients with persistent atrial fibrillation. PROMETEY – an open, multicenter, pilot study performed in the Russian Federation (part II) |
| title_short | Propafenone in restoring sinus rhythm among patients with persistent atrial fibrillation. PROMETEY – an open, multicenter, pilot study performed in the Russian Federation (part II) |
| title_sort | propafenone in restoring sinus rhythm among patients with persistent atrial fibrillation prometey an open multicenter pilot study performed in the russian federation part ii |
| topic | atrial fibrillation propafenone sinus rhythm maintenance multicenter study |
| url | https://cardiovascular.elpub.ru/jour/article/view/1006 |
| work_keys_str_mv | AT igfomina propafenoneinrestoringsinusrhythmamongpatientswithpersistentatrialfibrillationprometeyanopenmulticenterpilotstudyperformedintherussianfederationpartii AT aitarzimanova propafenoneinrestoringsinusrhythmamongpatientswithpersistentatrialfibrillationprometeyanopenmulticenterpilotstudyperformedintherussianfederationpartii AT avvetluzhsky propafenoneinrestoringsinusrhythmamongpatientswithpersistentatrialfibrillationprometeyanopenmulticenterpilotstudyperformedintherussianfederationpartii AT aaabramova propafenoneinrestoringsinusrhythmamongpatientswithpersistentatrialfibrillationprometeyanopenmulticenterpilotstudyperformedintherussianfederationpartii |